Related Experiment Video
Updated: Mar 1, 2026
08:14
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
8.7K
Hypercholesterolemia: The role of PCSK9.
Quantil M Melendez1, Sreevidhya T Krishnaji2, Catherine J Wooten1
1Department of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise (BRITE), College of Arts and Sciences, North Carolina Central University, Durham, NC 27707, USA.
Archives of Biochemistry and Biophysics
|June 8, 2017
Summary
Proprotein convertase subtilisin/kexin-9 (PCSK9) regulates low-density lipoprotein (LDL) cholesterol, impacting heart disease risk. This review explores PCSK9 functions, its link to metabolic issues, and hypercholesterolemia treatments.
Area of Science:
- Biochemistry and Molecular Biology
- Cardiovascular Disease Research
- Metabolic Syndrome Studies
Background:
- Heart disease is the leading cause of death in the US, often linked to high LDL cholesterol.
- Atherosclerotic plaque formation is exacerbated by elevated LDL cholesterol levels.
- Proprotein convertase subtilisin/kexin-9 (PCSK9) plays a key role in regulating LDL receptor expression and plasma LDL levels.
Purpose of the Study:
- To review the diverse functions and regulatory mechanisms of PCSK9.
- To elucidate the relationship between PCSK9, LDL receptors, and the inducible degrader of the LDL receptor (IDOL).
- To discuss current therapeutic strategies for managing hypercholesterolemia.
Main Methods:
- Literature review of PCSK9's role in lipid metabolism.
- Analysis of PCSK9's influence on LDL receptor homeostasis.
- Examination of PCSK9's association with metabolic abnormalities.
Main Results:
- PCSK9 significantly impacts LDL receptor expression and plasma LDL levels.
- PCSK9 is implicated in glucose intolerance, insulin resistance, obesity, inflammation, and hypertension.
- The influence of PCSK9 on metabolic health varies with age, sex, and ethnicity.
Conclusions:
- PCSK9 is a critical regulator of LDL cholesterol and has broader metabolic implications.
- Understanding PCSK9's interaction with IDOL is essential for developing targeted therapies.
- Current treatments for hypercholesterolemia are discussed in the context of PCSK9 regulation.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
01:26Atherosclerosis III: Management
520
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
520
01:29Cholesterol: Significance and Regulation
1.7K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.7K
01:26Coronary Artery Disease IV: Preventive Measures
773
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
773
01:29Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
597
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
597